These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 17634518

  • 21. Counseling postmenopausal women about preventive hormone therapy. AGS Clinical Practice Committee.
    J Am Geriatr Soc; 1996 Sep; 44(9):1120-2. PubMed ID: 8790245
    [No Abstract] [Full Text] [Related]

  • 22. Relationship between serum progesterone and tumor necrosis factor production in postmenopausal women undergoing estrogen/medroxyprogesterone therapy.
    Stopińska-Głuszak U, Jóźwiak J, Radomski D, Głuszak O, Roszkowski PI, Malejczyk J.
    Fertil Steril; 2009 Apr; 91(4 Suppl):1344-6. PubMed ID: 18554598
    [Abstract] [Full Text] [Related]

  • 23. Bisphosphonate and estrogen replacement therapy for postmenopausal periodontitis.
    Haimov-Kochman R, Kochman T, Stabholz A, Hochner-Celinkier D.
    Isr Med Assoc J; 2004 Mar; 6(3):173-7. PubMed ID: 15055276
    [No Abstract] [Full Text] [Related]

  • 24. Understanding the controversy about hormonal replacement therapy: insights from estrogen effects on experimental and clinical atherosclerosis.
    Arnal JF, Douin-Echinard V, Tremollières F, Terrisse AD, Sié P, Payrastre B, Guery JC, Bayard F, Gourdy P.
    Arch Mal Coeur Vaiss; 2007 Mar; 100(6-7):554-62. PubMed ID: 17893638
    [Abstract] [Full Text] [Related]

  • 25. Estradiol + drospirenone.
    Prescrire Int; 2007 Jun; 16(89):106. PubMed ID: 17590905
    [Abstract] [Full Text] [Related]

  • 26. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R.
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [Abstract] [Full Text] [Related]

  • 27. Drospirenone, a progestin with added value for hypertensive postmenopausal women.
    Archer DF.
    Menopause; 2007 Oct; 14(3 Pt 1):352-4. PubMed ID: 17414576
    [No Abstract] [Full Text] [Related]

  • 28. [Estrogens in menopause--therapy and prevention. I. Hormone substitution in climacteric and postmenopause].
    Wuttke W.
    Internist (Berl); 1996 Apr; 37(4):402-5. PubMed ID: 8655280
    [No Abstract] [Full Text] [Related]

  • 29. Rationale for later and less postmenopausal estrogen (PME).
    Barrett-Connor E.
    Aging (Milano); 1998 Apr; 10(2):158. PubMed ID: 9666213
    [No Abstract] [Full Text] [Related]

  • 30. Updated practical recommendations for hormone replacement therapy in the peri- and postmenopause.
    Birkhäuser MH, Panay N, Archer DF, Barlow D, Burger H, Gambacciani M, Goldstein S, Pinkerton JA, Sturdee DW.
    Climacteric; 2008 Apr; 11(2):108-23. PubMed ID: 18365854
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Postmenopausal hormone replacement therapy and atherosclerosis.
    Ho JE, Mosca L.
    Curr Atheroscler Rep; 2002 Sep; 4(5):387-95. PubMed ID: 12162939
    [Abstract] [Full Text] [Related]

  • 33. Gender-specific characteristics of atherosclerosis in menopausal women: risk factors, clinical course and strategies for prevention.
    Vitale C, Miceli M, Rosano GM.
    Climacteric; 2007 Oct; 10 Suppl 2():16-20. PubMed ID: 17882667
    [Abstract] [Full Text] [Related]

  • 34. Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen.
    Rozenberg S, Pornel B, Koninckx PR, Palacios S, Christiansen C.
    Hum Reprod; 2009 Jul; 24(7):1739-47. PubMed ID: 19351658
    [Abstract] [Full Text] [Related]

  • 35. Benefits of exogenous oestrogen in inhibiting stress-related coronary artery atherosclerosis.
    Clarkson TB, Kaplan JR, Shively CA, Klein KP.
    Br J Obstet Gynaecol; 1996 May; 103 Suppl 13():73-8; discussion 78-9. PubMed ID: 8624347
    [No Abstract] [Full Text] [Related]

  • 36. Nonvertebral "osteoporotic" fractures: a brain disease or bone disease?
    Birge SJ.
    Menopause; 2007 May; 14(1):1-2. PubMed ID: 17179791
    [No Abstract] [Full Text] [Related]

  • 37. Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapy.
    Bitzer J, Kenemans P, Mueck AO, FSDeducation Group.
    Maturitas; 2008 Mar 20; 59(3):209-18. PubMed ID: 18343056
    [Abstract] [Full Text] [Related]

  • 38. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 20; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 39. A prospective, randomized, double-blind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women.
    Sator PG, Sator MO, Schmidt JB, Nahavandi H, Radakovic S, Huber JC, Hönigsmann H.
    Climacteric; 2007 Aug 20; 10(4):320-34. PubMed ID: 17653959
    [Abstract] [Full Text] [Related]

  • 40. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
    Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, Economou EV, Siasou Z, Panoulis CP, Kalligerou I, Papadias C.
    Climacteric; 2008 Apr 20; 11(2):155-65. PubMed ID: 18365858
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.